Prognostic role of short physical performance battery in elderly hospitalized atrial fibrillation patients
- PMID: 40377853
- PMCID: PMC12331861
- DOI: 10.1007/s11739-025-03958-8
Prognostic role of short physical performance battery in elderly hospitalized atrial fibrillation patients
Abstract
Atrial Fibrillation (AF) is the most common supraventricular arrhythmia, especially in elderly, in whom may contribute to physical impairment. The Short Physical Performance Battery (SPPB) is particularly important for assessing the overall physical functionality but the prognostic role of functional limitation, assessed with the SPPB, in elderly hospitalized AF patients is unknown. The objective of this study is to assess the potential impact of functional disability, evaluated as SPPB < 8 points, on the prognosis of elderly patients with AF who are hospitalized. In this retrospective analysis, 1004 elderly patients were enrolled, of whom 620 women, with a mean age of 84 ± 7.1 years. The occurrence of cardiovascular events CVEs (non-fatal ischemic stroke, nonfatal myocardial infarction, cardiac revascularization or coronary bypass surgery, and cardiovascular death), total mortality occurrence were evaluated during a median follow-up of 3.2 years. In patients with SPPB ≥ 8 pt, the observed CVEs incidence was 3.8 events/100 patient-year compared to 12.4 events/100 patient-year in those with SPPB < 8 (p < 0.0001). The multivariate analysis model confirmed that SPPB < 8 was associated with an increased risk of CVEs by a factor of 2.78. In addition, the presence of pathological geriatric depression scale, previous use of Vitamin K Antagonists, were associated with an increased risk of CVEs in study participants. In contrast, statin therapy, male sex and renin-angiotensin-aldosterone system inhibitors are associated with a reduced risk of CVEs during follow-up. Hospitalized patients with AF that exhibits pathological SPPB score show a higher risk of CVEs and total mortality.
Keywords: Atrial Fibrillation; DOACs; Elderly; Short physical performance battery.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflicts of interest: The authors declare they have no conflict of interest. Ethical approval: The local Ethical Committee (Comitato etico Regione Calabria “Area Centro”) approved the protocol: code protocol number 2012.63 and 2022.361. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed consent: Informed consent was obtained from all subjects involved in the study. Consent for publication: All authors have read and agreed to the published version of the manuscript.
Figures


Similar articles
-
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280. Health Technol Assess. 2008. PMID: 18547499
-
Exercise for acutely hospitalised older medical patients.Cochrane Database Syst Rev. 2022 Nov 10;11(11):CD005955. doi: 10.1002/14651858.CD005955.pub3. Cochrane Database Syst Rev. 2022. PMID: 36355032 Free PMC article.
-
Echocardiography in newly diagnosed atrial fibrillation patients: a systematic review and economic evaluation.Health Technol Assess. 2013 Aug;17(36):1-263, v-vi. doi: 10.3310/hta17360. Health Technol Assess. 2013. PMID: 23985296 Free PMC article.
-
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.Cochrane Database Syst Rev. 2013 Aug 8;(8):CD008980. doi: 10.1002/14651858.CD008980.pub2. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2018 Mar 06;3:CD008980. doi: 10.1002/14651858.CD008980.pub3. PMID: 23925867 Updated.
-
Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.Health Technol Assess. 2010 Jun;14(31):iii-iv, 1-75. doi: 10.3310/hta14310. Health Technol Assess. 2010. PMID: 20569652
References
-
- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, ESCScientificDocumentGroup(2021) et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 10.1093/eurheartj/ehaa61 - PubMed
-
- Pastori D, Pignatelli P, Angelico F, Farcomeni A, Del Ben M, Vicario T et al (2015) Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. Chest 147(6):1644–1650. 10.1378/chest.14-2414 - PubMed
-
- Armentaro G, D’Arrigo G, Bo M, Cassano V, Miceli S, Pitino A, Tripepi G, Romeo SMG, Sesti G, Lip GYH, Pastori D, Gori M, Sciacqua A (2023) Medium-term and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation. Front Pharmacol. 10.3389/fphar.2023.1210560 - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical